-- Earnings Flash (ALPN) ALPINE IMMUNE SCIENCES Posts Q1 Revenue $13.6M
4:27PM ET 5/12/2022 MT Newswires...
Quotes Snapshot > ALPN
Alpine Immune Sciences Inc ALPN:NASDAQ
Last Price$7.55NASDAQ Previous Close - Last Trade as of 4:00PM ET 5/13/22
Today's Change+0.84(12.52%)
Bid (Size)$7.00 (1)
Ask (Size)$7.61 (2)
Day Low / High$6.62 - 7.70
Volume92.0 K
Read more news Recent News
Alpine Immune Q4 Loss Widens Amid Lower Revenue; Sees Enough Funds Through 2024
5:11PM ET 3/17/2022 MT NewswiresAlpine Immune Sciences (ALPN) on Thursday widened its net loss to $0.52 per share in Q4 from $0.27 per share a year earlier. Analysts polled by Capital IQ...
-- Earnings Flash (ALPN) ALPINE IMMUNE SCIENCES Posts Q4 Revenue $4.5M
4:05PM ET 3/17/2022 MT Newswires...
Alpine Says FDA Places Partial Clinical Hold on Study of Davoceticept Drug Cocktail in Advanced Malignancies
9:48AM ET 3/07/2022 MT NewswiresAlpine Immune Sciences (ALPN) said Monday the US Food and Drug Administration placed its clinical study of davoceticept in combination with pembrolizumab...
View all Commentary and Analysis
Alpine Immune Sciences, Inc. (ALPN) Reports Q1 Loss, Tops Revenue Estimates
4:55PM ET 5/12/2022 ZacksAlpine Immune Sciences, Inc. (ALPN) delivered earnings and revenue surprises of -47.06% and 2.07%,...
Alpine: Rest Before Rallying Again
12:08PM ET 4/25/2022 Seeking AlphaAlpine Immune Sciences (ALPN) Investor Presentation - Slideshow
3:44PM ET 1/10/2022 Seeking AlphaAlpine Immune Sciences (ALPN) Investor Presentation
11:29AM ET 8/12/2021 Seeking AlphaCompany Profile
Business DescriptionAlpine Immune Sciences, Inc. is a development-stage pharmaceutical company, which engages in the discovery of protein-based immunotherapies to treat cancer and autoimmune and inflammatory diseases. Its product pipeline includes inflammatory diseases, immuno-oncology, and engineered cellular therapies. The company was founded in March 2007 and is headquartered in Seattle, WA. View company web site for more details
| Address | 188 East Blaine Street Seattle, Washington 98102 |
| Phone | +1.206.788.4545 |
| Number of Employees | 48 |
| Recent SEC Filing | 05/12/2022 10-Q |
| Executive Chairman & Chief Executive Officer | Mitchell H. Gold |
| President & Head-Research & Development | Stanford L. Peng |
| Finance Director | Thaedra Thullberry |
| Chief Financial Officer, Secretary & Senior VP | James Paul Rickey |
Company Highlights
| Price Open | $6.72 |
| Previous Close | $6.71 |
| 52 Week Range | $6.00 - 15.14 |
| Market Capitalization | $229.0 M |
| Shares Outstanding | 30.3 M |
| Sector | Health Technology |
| Industry | Biotechnology | Next Earnings Announcement | 08/09/2022 |
Options Summary
| Call Open Interest (1d)* |  |
| Put Open Interest (1d)* | |
| Call Volume (1d)* | |
| Put Volume (1d)* | |
| Put Call Open Interest Ratio (1d)* | |
| Put Call Volume Ratio (1d)* | |
| * Data delayed by up to 15 minutes |
View all fundamentalsFundamentals
| Price / Earnings | N/A |
| Earnings per Share | -$1.97 |
| Beta vs. S&P 500 | N/A |
| Revenue | $705.0 K |
| Net Profit Margin | -214.70% |
| Return on Equity | -59.07% |
Analyst Ratings as of 10/14/2021
| Buy | |
| Overweight | |
| Hold | |
| Underweight | |
| Sell | |
Consensus Recommendation | |